Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Klaus-Uwe Kirchgaessler
Observed name:
KLAUS-UWE KIRCHGAESSLER
Institution:
F. Hoffmann-La Roche AG
Observed institutions:
F. Hoffmann-La Roche AG,
Cedars-Sinai Medical Center,
Ruhrlandklinik,
Imperial College London,
University of Turin,
University of Duisburg-Essen,
Vanderbilt University Medical Center
show all 7
OpenAlex ID:
A5110553219
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
2019
·
Toby M Maher
, Tamera J Corte
, et al.
·
The Lancet Respiratory Medicine
·
695
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
2016
·
Steven D Nathan
, Carlo Albera
, et al.
·
The Lancet Respiratory Medicine
·
370
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
2017
·
Lisa H. Lancaster
, Joao A. de Andrade
, et al.
·
European Respiratory Review
·
320
PDF
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis
2016
·
Michael Kreuter
, Wim Wuyts
, et al.
·
The Lancet Respiratory Medicine
·
232
PDF
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
2021
·
Michael Kreuter
, Joyce S. Lee
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
230
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial
2020
·
Jürgen Behr
, Steven D Nathan
, et al.
·
The Lancet Respiratory Medicine
·
150
PDF
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
2018
·
Vincent Cottin
, Dirk Koschel
, et al.
·
ERJ Open Research
·
132
PDF
Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis
2017
·
Vincent Cottin
, David M. Hansell
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
118
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
2016
·
Michael Kreuter
, Francesco Bonella
, et al.
·
Thorax
·
95
PDF
Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment
2019
·
Steven D. Nathan
, Ulrich Costabel
, et al.
·
Respiratory Medicine
·
86
PDF
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis
2016
·
Michael Kreuter
, Marlies S. Wijsenbeek
, et al.
·
European Respiratory Journal
·
73
PDF
Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis
2018
·
Paolo Spagnolo
, Michael Kreuter
, et al.
·
Respiration
·
68
The 6-min walk test as a primary end-point in interstitial lung disease
2022
·
Sergio Harari
, Athol U. Wells
, et al.
·
European Respiratory Review
·
65
PDF
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
2018
·
Toby M Maher
, Tamera J Corte
, et al.
·
BMJ Open Respiratory Research
·
62
PDF
Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
2018
·
Wim A Wuyts
, Caroline Dahlqvist
, et al.
·
BMJ Open Respiratory Research
·
59
PDF
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
2019
·
Ulrich Costabel
, Carlo Albera
, et al.
·
Respiratory Research
·
48
PDF
Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
2018
·
Steven D Nathan
, Lisa H Lancaster
, et al.
·
BMJ Open Respiratory Research
·
47
PDF
Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis
2019
·
Michael Kreuter
, David J. Lederer
, et al.
·
CHEST Journal
·
46
PDF
A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
2022
·
Toby M. Maher
, Courtney Schiffman
, et al.
·
Respiratory Research
·
37
PDF
Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss
2021
·
Stéphane Jouneau
, Bruno Crestani
, et al.
·
Respiration
·
36
Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study – Rationale and study design
2018
·
Jürgen Behr
, Steven D. Nathan
, et al.
·
Respiratory Medicine
·
32
PDF
Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
2019
·
Wim A. Wuyts
, Caroline Dahlqvist
, et al.
·
Respiratory Research
·
31
PDF
Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis
2019
·
Carlo Vancheri
, Alfredo Sebastiani
, et al.
·
Respiratory Medicine
·
30
PDF
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
2019
·
Toby M. Maher
, Lisa H. Lancaster
, et al.
·
Annals of the American Thoracic Society
·
29
Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015
2019
·
C. Magnus Sköld
, Lisen Arnheim-Dahlström
, et al.
·
Respiratory Medicine
·
26
PDF
Show more works
View as search
Works count:
69
Citation count:
3,321
H-index:
25
I10-index:
32
Year
Topic
Type